Table 2.
mRNA-based dendritic cell cancer vaccines
| Trial phase | Target antigen | Cancer type | Combination | Vaccine route of administration | Sponsor | |
|---|---|---|---|---|---|---|
| NCT05000801 | Not described | WT1, hTERT, and survivin-loaded dendritic cells | Acute myeloid leukaemia | With follow-up care | Not described | Affiliated Hospital to Academy of Military Medical Sciences (Beijing, China) |
| NCT01686334 | 2 | WT1 | Acute myeloid leukaemia | With follow-up care | Intradermal | Antwerp University Hospital (Antwerp, Belgium) |
| NCT02649829 | 1/2 | WT1 | Pleural mesothelioma | With standard therapy | Intradermal | Antwerp University Hospital |
| NCT04911621 | 1/2 | WT1 | High-grade glioma and diffuse intrinsic pontine glioma | With chemoradiation (with or without standard therapy) | Intradermal | Antwerp University Hospital |
| NCT02649582 | 1/2 | WT1 | Glioblastoma multiforme | With temozolomide | Intradermal | Antwerp University Hospital |
| NCT04157127 | 1 | Pancreatic adenocarcinoma mRNA and lysate | Pancreatic adenocarcinoma | With standard therapy | Intradermal | Baylor College of Medicine (Houston, TX, USA) |
| NCT00639639 | 1 | Cytomegalovirus pp65-LAMP | Glioblastoma multiforme | With autologous lymphocyte transfer and Td | Intradermal | Duke University (Durham, NC, USA) |
| NCT03688178 | 2 (randomised) | Cytomegalovirus pp65-flLAMP | Glioblastoma multiforme | With temozolomide, varlilumab, and Td | Intradermal | Duke University |
| NCT04335890 | 1 | Autologous tumour RNA with gp100, tyrosinase, PRAME, MAGE-A3, IDO, and different driver mutations | Uveal melanoma | With standard therapy | Intravenous | Hasumi International Research Foundation |
| NCT02465268 | 2 (randomised) | HCMV pp65-shLAMP or pp65-flLAMP | Glioblastoma multiforme | With temozolomide, GM-CSF, and Td | Not described | Immunomic Therapeutics |
| NCT01995708 | 1 | CT7, MAGE-A3, and WT1 (Langerhans-type dendritic cells) | Multiple myeloma | With standard treatment | Intradermal | Memorial Sloan Kettering Cancer Center (New York, NY, USA) |
| NCT01456104 | 1 | Trp2 (Langerhans-type dendritic cells) | Melanoma | None | Not described | Memorial Sloan Kettering Cancer Center |
| NCT01197625 | 1/2 | hTERT, survivin, and mRNA from primary prostate cancer tissue | Prostate cancer | None | Not described | Oslo University Hospital (Oslo, Norway) |
| NCT03548571 | 2/3 | hTERT, survivin, and mRNA from autologous tumour stem cells | Glioblastoma multiforme | With temozolomide | Intradermal | Oslo University Hospital |
| NCT01983748 | 3 (randomised) | Autologous tumour RNA | Uveal melanoma | None | Intravenous | University Hospital Erlangen (Erlangen, Germany) |
| NCT03083054 | 1/2 | WT1 | Myelodysplastic syndromes, acute myeloid leukaemia | None | Not described | University of Campinas (Campinas, Brazil) |
| NCT04963413 | 1 | Cytomegalovirus pp65-flLAMP | Glioblastoma multiforme | With temozolomide, GM-CSF, and Td | Not described | University of Florida (Gainesville, FL, USA) |
| NCT03396575 | 1 | TTRNA | Brainstem gliomas | With cyclophosphamide, fludarabine, temozolomide, TTRNA-xALT, autologous haematopoietic stem cells, GM-CSF, and Td | Intradermal | University of Florida |
| NCT01326104 | 1/2 | TTRNA | Medulloblastoma, neuroectodermal tumour | With TTRNA-xALT | Intradermal | University of Florida |
Trials with recruitment status: “not yet recruiting,” “recruiting,” and “active, not recruiting” were found on ClinicalTrial.gov with the search terms: “cancer” and “RNA, vaccine” on Feb 7, 2022, and through a PubMed search (see Search strategy and selection criteria panel). Td=tetanus-diphtheria toxoid vaccine. TTRNA=tumour mRNA-pulsed autologous dendritic cells. TTRNA-xALT=tumour-specific autologous lymphocyte transfer.